MicroRNA-Based Combinatorial Cancer Therapy: Effects of MicroRNAs on the Efficacy of Anti-Cancer Therapies.
The susceptibility of cancer cells to different types of treatments can be restricted by intrinsic and acquired therapeutic resistance, leading to the failure of cancer regression and remission. To overcome this problem, a combination therapy has been proposed as a fundamental strategy to improve therapeutic responses; however, resistance is still unavoidable. MicroRNA (miRNAs) are associated with cancer therapeutic resistance. The modulation of dysregulated miRNA levels through miRNA-based therapy comprising a replacement or inhibition approach has been proposed to sensitize cancer cells to other anti-cancer therapies. The combination of miRNA-based therapy with other anti-cancer therapies (miRNA-based combinatorial cancer therapy) is attractive, due to the ability of miRNAs to target multiple genes associated with the signaling pathways controlling therapeutic resistance. In this article, we present an overview of recent findings on the role of therapeutic resistance-related miRNAs in different types of cancer. We review the feasibility of utilizing dysregulated miRNAs in cancer cells and extracellular vesicles as potential candidates for miRNA-based combinatorial cancer therapy. We also discuss innate properties of miRNAs that need to be considered for more effective combinatorial cancer therapy.
['Seo|Hyun Ah|HA|', 'Moeng|Sokviseth|S|', 'Sim|Seokmin|S|', 'Kuh|Hyo Jeong|HJ|', 'Choi|Soo Young|SY|', 'Park|Jong Kook|JK|']
D000970:Antineoplastic Agents D019008:Drug Resistance, Neoplasm D004357:Drug Synergism D000067128:Extracellular Vesicles D015972:Gene Expression Regulation, Neoplastic D006801:Humans D035683:MicroRNAs D009369:Neoplasms
cancer microRNA therapeutic resistance combination therapy chemosensitization